Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Abstract

BACKGROUND:

Interim PET scans in HIV-negative patients with Hodgkin lymphoma has emerged as one of the most important prognostic tools. However, equivalent studies in HIV-positive patients are yet to be performed.

OBJECTIVE:

We evaluated the prognostic value of interim [18F]-fluoro-2-deoxy-D-glucose-PET (18F-FDG PET) after two or three cycles of chemotherapy using adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) with concomitant HAART in HIV-positive patients with Hodgkin lymphoma.

METHODS:

Patients with advanced HIV-Hodgkin lymphoma (HIV-HL) from six UK centres were included. Interim PET scans after two or three cycles of ABVD (PET-2 or PET-3) were carried out. Prognostic analysis correlated the 2-year progression-free survival (PFS) rate with the interim PET result.

RESULTS:

Twenty-three evaluable patients were assessed, 21 achieved a negative interim PET and 22 achieved complete remission by computerized tomography scan criteria after ABVD therapy. After a median follow-up of 27 months (range 12-50), disease progression was seen in one patient. Treatment failure was seen in one of the two interim PET-positive patients and none of the interim PET-negative patients. The 2-year PFS for interim PET-positive patients was 50%, and 100% for interim PET-negative patients (P = 0.0012).

CONCLUSION:

A negative interim 18F-FDG PET result is highly predictive of treatment success in HIV-HL patients.

• Authors: Jessica Okosun, Victoria Warbey, Kate Shaw, Silvia Montoto, Paul Fields, Robert Marcus, Andres Virchis, Christopher McNamara, Mark Bower, Kate Cwynarski
• Journal: AIDS (London, England) (AIDS) Vol. 26 Issue 7 Pg. 861-5 (Apr 24 2012) ISSN: 1473-5571 [Electronic] England
• PMID: 22333746 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents
• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• Bleomycin
• Vinblastine
• Dacarbazine
• Doxorubicin

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Antiretroviral Therapy, Highly Active
• Bleomycin (therapeutic use)
• Dacarbazine (therapeutic use)
• Disease-Free Survival
• Doxorubicin (therapeutic use)
• Female
• Fluorodeoxyglucose F18
• Follow-Up Studies
• HIV Infections (drug therapy)
• Hodgkin Disease (diagnostic imaging, drug therapy)
• Humans
• Lymphoma, AIDS-Related (diagnostic imaging, drug therapy)
• Male
• Middle Aged
• Positron-Emission Tomography (methods)
• Radiopharmaceuticals
• Retrospective Studies
• Tomography, X-Ray Computed
• Treatment Outcome
• Vinblastine (therapeutic use)